AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
AUCKLAND, New Zealand, Aug. 4, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive...
Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance
(All amounts are in U.S. dollars unless otherwise indicated)
TORONTO, July 28,...
Quarter-Over-Quarter Production Growth Drives Record Free Cash Flow Generation; On-Track to Achieve Annual Guidance
(All amounts are in U.S. dollars unless otherwise indicated)
TORONTO, July 28,...
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
Original research by NEB scientists contributes to the kit's unprecedented low bias,speed, shelf life, and input range
IPSWICH, Mass., July 22, 2025 /PRNewswire/ -- New England Biolabs...
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...